PCN139 FINAL QUALITY OF LIFE (QOL) RESULTS WITH GEOGRAPHICAL ANALYSIS FOR SUNITINIB VERSUS INTERFERON-ALFA, AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
Abstract
Authors
D Cella MD Michaelson AG Bushmakin JC Cappelleri C Charbonneau ST Kim JZ Li RJ Motzer